DrugPatentWatch Database Preview
DUAVEE Drug Profile
see a sample report or, see our see our flat-rate plans
When do Duavee patents expire, and when can generic versions of Duavee launch?
Duavee is a drug marketed by Wyeth Pharms Pfizer and is included in one NDA. There are four patents protecting this drug.
This drug has sixty-four patent family members in forty countries.
The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.
Summary for DUAVEE
| International Patents: | 64 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 6 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DUAVEE |
| DailyMed Link: | DUAVEE at DailyMed |
Generic Entry Opportunity Date for DUAVEE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for DUAVEE
| Ingredient-type | Estrogens, Conjugated (USP) |
| Drug Class | Estrogen Estrogen Agonist/Antagonist |
| Mechanism of Action | Estrogen Receptor Agonists Selective Estrogen Receptor Modulators |
US Patents and Regulatory Information for DUAVEE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms Pfizer | DUAVEE | bazedoxifene acetate; estrogens, conjugated | TABLET;ORAL | 022247-001 | Oct 3, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Wyeth Pharms Pfizer | DUAVEE | bazedoxifene acetate; estrogens, conjugated | TABLET;ORAL | 022247-001 | Oct 3, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Wyeth Pharms Pfizer | DUAVEE | bazedoxifene acetate; estrogens, conjugated | TABLET;ORAL | 022247-001 | Oct 3, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Wyeth Pharms Pfizer | DUAVEE | bazedoxifene acetate; estrogens, conjugated | TABLET;ORAL | 022247-001 | Oct 3, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Wyeth Pharms Pfizer | DUAVEE | bazedoxifene acetate; estrogens, conjugated | TABLET;ORAL | 022247-001 | Oct 3, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for DUAVEE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Pharms Pfizer | DUAVEE | bazedoxifene acetate; estrogens, conjugated | TABLET;ORAL | 022247-001 | Oct 3, 2013 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for DUAVEE
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,787,538 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | ➤ Sign Up |
| 6,127,404 | Tissue selective compounds in the treatment of endometrial proliferation | ➤ Sign Up |
| 7,449,455 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | ➤ Sign Up |
| 6,835,729 | 2-phenyl-1-[4(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | ➤ Sign Up |
| 7,132,417 | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents | ➤ Sign Up |
| 6,232,307 | Tissue selective compounds in the treatment of ovarian cancer | ➤ Sign Up |
| 6,951,852 | 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indoles as estrogenic agents | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
see a sample report or, see our see our flat-rate plans
International Patents for DUAVEE
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Hungary | 9700777 | ➤ Sign Up |
| China | 1938272 | ➤ Sign Up |
| Austria | 206701 | ➤ Sign Up |
| Portugal | 802183 | ➤ Sign Up |
| European Patent Office | 1732890 | ➤ Sign Up |
| South Korea | 20060135866 | ➤ Sign Up |
| Guatemala | 200500078 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for DUAVEE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2009 00035 | Denmark | ➤ Sign Up | |
| 0416 | Netherlands | ➤ Sign Up | 300416, 20170415, EXPIRES: 20220414 |
| 2009007,C0802183 | Lithuania | ➤ Sign Up | PRODUCT NAME: BAZEDOXIFENUM; REGISTRATION NO/DATE: EU/1/09/511/001 - EU/1/09/511/004 20090417 |
| 4 | Finland | ➤ Sign Up | |
| C/GB09/045 | United Kingdom | ➤ Sign Up | PRODUCT NAME: BAZEDOXIFENE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/09/511/001 20090417; UK EU/1/09/511/002 20090417; UK EU/1/09/511/003 20090417; UK EU/1/09/511/004 20090417 |
| C0048 | France | ➤ Sign Up | PRODUCT NAME: BAZEDOXIFENE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/09/511/001 DU 20090417; REGISTRATION NO/DATE AT EEC: EU/1/09/511/001-004 DU 20090417 |
| 0802183/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: BAZEDOXIFEN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58732 12.01.2010 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
